Among the antihypertensive agents, olmesartan has been reported to protect against oxidative stress in rats, via the induction of nuclear factor-erythroid-2-related factor 2 (Nrf2) signaling pathways.4 Olmesartan medoxomil is a long-acting angiotensin II type I receptor (AT1R) antagonist approved for the treatment of mild to severe hypertension, alone or in combination with other agents. Here, NFE2L2 is linked to Hypertension.